Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Wellness Action Plan Trial Addressing Childhood Obesity

NCT02185248
View directory record Official record
Conditions
Childhood Obesity
Interventions
Wellness Action Plan
Behavioral
Lead sponsor
Roohi Kharofa, MD, MPH
Other
Eligibility
30 Months to 14 Years
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 23, 2026, 1:51 PM EDT
Terminated Not applicable Interventional

Strategies in Patients Undergoing Repeat AF Ablation

NCT05185310
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ablation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen B Verdiperstat

NCT04436510
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Matching Placebo, Verdiperstat
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 23, 2026, 1:51 PM EDT
Recruiting Phase 2 Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 1:51 PM EDT
Active, not recruiting Not applicable Interventional

CARE (Chemotherapy Alopecia REduction)

NCT07201389
View directory record Official record
Conditions
Breast Cancer, Breast - Female, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Chemotherapy Induced Alopecia
Interventions
Scalp Cooling by DigniCap
Device
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations

NCT04580797
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06700841 IR, PF-06700841 MR1, PF-06700841 MR2, PF-06700841 MR3, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Not applicable Interventional Results available

Stress in Inflammatory Bowel Disease

NCT05202418
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Psychological
Interventions
Biofeedback Enhanced Treatment
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 23, 2026, 1:51 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 23, 2026, 1:51 PM EDT
Not listed No phase listed Observational

Diaphragmatic Breathing Exercises in Total Knee Arthroplasty Patients

NCT04336579
View directory record Official record
Conditions
Anesthesia and Analgesia
Interventions
Diaphragmatic Breathing
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 23, 2026, 1:51 PM EDT
Completed No phase listed Observational

A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021

NCT01498497
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
EUR-1100, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

NCT01863186
View directory record Official record
Conditions
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Interventions
Lofexidine HCl, Placebo, Open Label Lofexidine HCL
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Clovis, California • Escondido, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 2 Interventional

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

NCT06628362
View directory record Official record
Conditions
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 1:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy

NCT04791761
View directory record Official record
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen, Opioid disposal pouch, Opioid disposal education
Drug · Other
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 23, 2026, 1:51 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis.

NCT07605338
View directory record Official record
Conditions
Plaque, Dental, Gingivitis
Interventions
Colgate SNaP Total 10/10, 1.5 Taurate, Colgate Great Regular Flavor Toothpaste, Flat Trimmed Extra Clean TB
Drug · Other
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 23, 2026, 1:51 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Months to 12 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 1:51 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

NCT01813019
View directory record Official record
Conditions
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
San Diego, California • Watertown, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 23, 2026, 1:51 PM EDT
Terminated Phase 3 Interventional

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

NCT00137345
View directory record Official record
Conditions
Kidney Transplant
Interventions
sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
13 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

NCT00899847
View directory record Official record
Conditions
Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions
Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone
Procedure · Drug · Radiation + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

NCT05171335
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lenvatinib, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency

NCT02991144
View directory record Official record
Conditions
Ornithine Transcarbamylase (OTC) Deficiency
Interventions
scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen
Genetic · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 23, 2026, 1:51 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

NCT04459416
View directory record Official record
Conditions
Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
Interventions
Acupuncture, opioid, Assessments
Other · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 1:51 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

NCT01511978
View directory record Official record
Conditions
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Interventions
Continuous 3,4-DAP, Taper 3,4-DAP to Placebo
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
7
States / cities
Sacramento, California • Indianapolis, Indiana • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 23, 2026, 1:51 PM EDT